Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Six cases of methyldopa hepatitis, including two in which the patients died are reported; and 77 cases from the literature are reviewed. Patients in whom severe hepatotoxic reactions to methyldopa develop usually complain of prodromal symptoms typical of hepatitis, often with fever, one to four weeks after therapy is initiated. Jaundice, when it occurs, is usually manifest within three months. Asymptomatic, transient elevations of serum transaminase levels may occur in patients receiving methyldopa. However, since the clinical and histologic features of hepatic injury from methyldopa are indistinguishable from viral hepatitis, it is suggested that the incidence of this iatrogenic disease is higher than generally appreciated. Serum transaminase levels should be determined at the initiation of therapy with methyldopa and four weeks later. Moreover, any patient who has unexplained fever or the prodromal symptoms of hepatitis should undergo liver chemistry studies immediately.
 ...
PMID:Methyldopa Hepatitis. A report of six cases and review of the literature. 93 54

We retrospectively studied 2,695 patients admitted to the Department of Medicine over a 10-month period in 1990 to determine the incidence of drug-related hospitalization. A drug-related problem was identified as the primary cause of hospitalization in 109 (4.0%) admissions. The incidence was significantly greater in the elderly group as compared with the non-elderly group (5.2% vs 3.2%). Non-steroidal anti-inflammatory drugs, hypoglycemic agents, herbal medicine, adrenocorticosteroids and antihypertensive drugs were most often involved. The five most common adverse events were upper gastrointestinal tract bleeding, skin rashes, hypoglycemia, hypercorticism and hepatitis. Iatrogenic disease was fatal in 2 cases. Patients used drugs without medical supervision in 45 cases. In view of the increasing complexity of modern pharmacotherapy and the popularity of self-medication in our society, educational efforts should be enhanced for medical professionals and the general population to reduce the risk of drug-related hospitalization.
 ...
PMID:A survey on drug-related hospitalization in a community teaching hospital. 845 78

We examined stigma in persons with hepatitis C and its relationship with mood and adjustment to illness. We studied 87 persons awaiting interferon treatment for hepatitis C at St James's Hospital, Dublin. Stigma was assessed using Fife's Experience of Illness scale. A structured clinical interview was used to establish DSM-IV diagnosis. The Hospital Anxiety and Depression Scale (HADS) and Beck Depression Inventory (BDI) were also used as measures of mood. Factor analysis and clustering around latent variables analysis were used to assess scale structure and reliability. The stigma scale had an overall reliability of 0.94. A strong dimension of fear of disclosure emerged, from item analysis, together with dimensions of social isolation and social rejection. Stigma was higher in those in manual occupations and the unemployed than in those in non-manual occupation. There were high levels in those with disease associated with injecting drug use and iatrogenic disease caused by transfusion or anti-D blood products, and low levels in those who had been treated for haemophilia with contaminated products or whose hepatitis was of unknown origin. Adjusted for confounders, a 1-decile increase in stigma score had an odds ratio of 1.4 for DSM-IV depression and similar associations with depression on the HADS and BDI. Stigma was also associated with poorer work and social adjustment, lower acceptance of illness, higher subjective levels of symptoms and greater subjective impairment of memory and concentration. These associations were replicated in the non-depressed subsample. The results underline the strong link between stigma and well-being in hepatitis C. However, they also suggest that stigma is a complex construct that will require further research to elucidate.
 ...
PMID:Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. 1701 Apr 90

Ethnographic material dealing with the contemporary viral hepatitis B and C epidemics in Cameroon provide a window onto the acute constraints and shortcomings of hospital care for patients, families, and health care workers. Although viral hepatitis has long been an invisible epidemic in international and global public health regimes, in Cameroon, it is diagnosed, made visible, and felt as a financially daunting and feared disease. Building on Ann Stoler's framework of imperial ruins, I consider hepatitis as an iatrogenic disease, emerging from scarce and unsound hospital infrastructures, such as blood transfusion techniques, as well as colonial public health vaccination practices. Such hospital technologies continue to produce anxieties, risk and excessive health expenses and hence cast their shadows on the future.
 ...
PMID:Viral Hepatitis and a Hospital Infrastructure in Ruins in Cameroon. 3042 6